How to Read a Peptide Study: Cell, Animal and Human Evidence Explained

Almost every claim about a research peptide traces back to a study. The trouble is that “a study showed” can mean anything from cells in a dish to a 2,000-person randomized trial. Those are very different kinds of evidence, and blurring them is the most common mistake in peptide marketing and in peptide reading alike.

This guide explains the evidence ladder used in our research guides, what each rung can and can’t tell you, why so many animal results never translate to people, how to read a paper quickly, and the red flags to watch for.

The short answer

• Evidence comes in levels: cell (in vitro) studies, animal studies, small human studies, randomized controlled trials, and systematic reviews that pool trials together.
• Each level answers a different question. Cell studies show what can happen; animal studies show what happens in a living system; only controlled human trials show what happens in people, compared with chance.
• Most promising early results don’t survive. A widely cited analysis estimates that about 90% of drug candidates entering clinical trials fail.
• Red flags include mouse data presented as if it applied to people, one research group behind all the evidence, no control group, and biomarkers sold as outcomes.
• Our compound guides show an evidence ladder so you can see at a glance where each one stands.

The evidence ladder, rung by rung

The hierarchy of evidence, also called the levels of evidence, ranks study designs by how well they guard against bias and chance when answering a question about effects in people. Cell and animal studies sit at the base, randomized controlled trials sit above them, and systematic reviews and meta-analyses of well-run trials sit at the top.

Cell studies (in vitro)

Researchers expose cultured cells or tissue to a compound and measure what changes. These studies are fast, cheap and good at revealing mechanisms: which receptor a peptide binds, which genes switch on, which pathway responds. What they can’t show is whether the compound reaches that tissue in a living body, at what concentration, or with what side effects. Concentrations in a dish are often far higher than anything tissues would see, and contamination such as endotoxin can mimic real effects.

Animal studies (in vivo)

Mice and rats add the whole body: absorption, distribution, metabolism, toxicity, and effects on behaviour or on models of disease. But species differ in metabolism, receptor biology and lifespan; disease models only approximate human illness; and animal studies are often small and published selectively.

Small human studies

Case reports, pilot studies and open-label trials show whether something is feasible and flag early safety signals. Without a control group, though, they can’t separate a compound’s effect from placebo, natural recovery or regression to the mean, the tendency of unusually bad measurements to drift back toward average on their own.

Randomized controlled trials

Participants are randomly assigned to the compound or a comparison, ideally with neither they nor the researchers knowing who received what. Pre-registered endpoints, adequate size and independent replication make randomized trials the standard for judging effects in people. Drug development runs them in phases: phase 1 tests safety in small groups, phase 2 looks for early signs of efficacy, and phase 3 confirms effects in large populations.

Systematic reviews and meta-analyses

These pool every eligible study on a question using a method fixed in advance. They are only as good as the studies they include. The GRADE system, widely used in medicine, rates the certainty of a body of evidence from high to very low.

Why animal results often fail in people

• Species differ. Receptors, enzymes and metabolic rates vary, so a compound can behave differently in a mouse than in a person.
• Models aren’t diseases. A chemically induced injury in a young, healthy rat is not the same as a chronic condition in an older person.
• Exposure differs. Amounts, routes and timing in animal studies rarely map neatly onto people.
• Small studies and selective publication. Positive results are more likely to be published, which inflates the apparent effect.
• Reproducibility. In a well-known 2012 report, scientists at the company Amgen could confirm the findings of only 6 of 53 landmark preclinical cancer studies.

The result is a long attrition funnel: most candidates that look promising in animals never become medicines, and about nine in ten that enter human trials fail along the way.

How to read a paper in ten minutes

• Skip to the methods. The abstract is the authors’ summary; the methods tell you what was actually done.
• Identify the subjects. Cells, animals or people, and how many?
• Look for a control group, randomization and blinding.
• Check what was measured. A biomarker, such as a blood level, is not the same as an outcome that matters, such as healing or survival.
• Read the size of the effect, with its confidence interval, not just whether it was “significant.”
• Check registration. Trials should be registered in advance, for example on ClinicalTrials.gov, and report what they planned to measure.
• Note who funded and ran it, and whether an independent group has replicated it.
• Check the journal and any corrections or retractions.

For clinical trials, also check which analysis a headline figure uses; our retatrutide phase 3 guide shows how one trial can honestly report two different numbers.

Red flags in peptide claims

• “Studies show” with no citation you can check.
• Mouse or cell results described as if they applied to people.
• All the evidence coming from one laboratory or one country’s research tradition. Our BPC-157 safety guide discusses this for one popular peptide.
• “No side effects” based on a handful of participants.
• Results for an approved drug borrowed to promote a research compound.
• Testimonials, before-and-after photos or anecdotes presented as evidence.
• Percentages with no baseline, no control group and no measure of uncertainty.

Where common research compounds stand

Even compounds high on the ladder remain unapproved until regulators decide, and research-grade versions are laboratory reagents, not the products tested in trials.

Research peptides with a published literature

Each compound below has a published record of cell and animal studies and, for some, small human studies, which our compound guides weigh using the approach above. Janoshik test reports for all four are listed on our Lab Testing page.

Frequently asked questions